BACKGROUNDS: The incidence of @entity320 is increasing by about 2-5% per year, exceeding an incidence of all other @entity5 . Adjuvant immunotherapy with @entity16216 ( @entity16216 ) as per the ECOG 1684 trial Kirkwood's schema is still recommended as a standard. @entity16216 should be started within 60 days after a surgical procedure. Meaningful adjuvant immunotherapy is based on radical surgical excision, an investigation of the sentinel node and regional lymph node dissection, if indicated. Current research aims to utilize routinely usable biomarkers in order to define @entity1 who would explicitly profit from @entity16216 . DESIGN: The authors present a review of @entity16216 trials, focusing on the management of adverse effects of @entity16216 and on biomarkers. This review also discusses the initial own experiences at the Oncology Centre in Hradec Kr  lov  . CONCLUSION: @entity320 is a @entity5 . Immunotherapy with @entity16216 is considered to be the only therapeutic modality so far that has been proven to prolong relapse-free survival and overall survival (in short-time criterion) in adjuvant setting. However, the results of these trials are inconsistent and particular biomarkers of therapeutic response have not been defined yet.

[High-dose interferon alpha in treatment of XXXX with @entity320 , monitoring of predictive and prognostic biomarkers].

@entity5 :: ('MESH:D009369', 'Disease') :: ['very immunogenic tumour', 'tumors'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity16216 :: ('MESH:C535530', 'Disease') :: ['high-dose interferon', 'HDI'] @entity320 :: ('MESH:D008545', 'Disease') :: ['Malignant melanoma', 'malignant melanoma']
@entity1 :: (9606,Species) :: ['patients']
